These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23537524)

  • 1. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
    Tesařová P; Tesař V
    Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?
    Izzedine H; Soria JC; Escudier B
    J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal involvement in preeclampsia: similarities to VEGF ablation therapy.
    Müller-Deile J; Schiffer M
    J Pregnancy; 2011; 2011():176973. PubMed ID: 21494322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
    Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
    Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF inhibition and renal thrombotic microangiopathy.
    Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
    N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
    Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
    Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renovascular effects of antiangiogenic drugs].
    Deray G; Janus N; Aloy B; Launay-Vacher V
    Bull Cancer; 2016; 103(7-8):662-6. PubMed ID: 27318610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nephrotoxicity--proteinuria and hypertension--].
    Ando M
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF inhibition, hypertension, and renal toxicity.
    Hayman SR; Leung N; Grande JP; Garovic VD
    Curr Oncol Rep; 2012 Aug; 14(4):285-94. PubMed ID: 22544560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
    Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
    Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.